Clinical Trial DRUG STML-701-0114
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- Principal Investigator
- Jeffrey Raizer
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.DRUG STML-701-0114
- The goal of this research study is to find out if SL-701 is safe and tolerable and what effect it has on brain tumors.
- SL-701 is an experimental medication. This means that the United States Food and Drug Administration (FDA) has not approved SL-701. SL-701 is a type of anti-cancer vaccine made up of parts of 3 different short proteins called “peptides” which are also found in certain brain tumors. The vaccine is intended to activate the immune system to recognize and kill the brain tumor cells that have the same protein.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have tumor recurrence (cancer came back) or progression (cancer is worsening)after initial (first) treatment.
- Participants who received prior cancer chemotherapy with bevacizumab or other VEGF?VEGFR-directed agents (check with the study doctor for any exclusions) cannot participate in this study.
- Description of Treatment
- Participants will receive SL-701 as a vaccine (shot by needle) along with medications that will make the immune response stronger. These medications are referred to as adjuvants. The adjuvant medications are FDA approved. Participants will come in every 2 weeks for 22 weeks and then about once a month after that. Participants will remain on the study until their tumor gets worse or the study doctor feels it is in their best interest to stop.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
last updated: 04-Mar-15 01:00 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.